1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024

  • December 2015
  • 52 pages
  • ID: 3565273
In this report:
JAPAN EXHIBITED ##,## DIAGNOSED PREVALENT CASES OF SSS IN 2014, WHICH IS EXPECTED TO RISE TO ##,## CASES IN 2024 AT AN AGR OF ##.##%.
ON THE OTHER HAND, SPAIN DEMONSTRATED THE LOWEST NUMBER OF PSS DIAGNOSED PREVALENT CASES IN 2014 AT ##,## CASES, WHICH IS EXPECTED TO INCREASE TO ##,## CASES IN 2024 AT AN AGR OF ##.##%.
JAPAN EXHIBITED ##,## DIAGNOSED PREVALENT CASES OF PSS IN 2014, WHICH IS EXPECTED TO RISE TO ##,## CASES IN 2024 AT AN AGR OF ##.##%.

Summary

Table of Contents

Search Inside

EpiCast Report: Sjögren's Syndrome - Epidemiology Forecast to 2024

Brief

Sjögren's syndrome is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a big variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS contain the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort criteria. The European classification criteria, which were revised by the American-European Consensus Group, are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent farther complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.

GlobalData epidemiologists estimate that within the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, Japan (JP)), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate of ~1.0 percent over the forecast period. Throughout the forecast period, the U.S. will have the more important number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjögren's syndrome will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjögren's syndrome will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of ~87.0 percent in the UK and the US to a high of ~98.0 percent in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.

Overview

- The Sjögren's Syndrome EpiCast Report offers an overview of the risk factors, comorbidities, and the overall and historical trends for SS, which comprises both primary Sjögren's syndrome and secondary Sjögren's syndrome, in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, broken down by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.

- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The SS EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall SS market.

- Quantify patient populations in the overall SS market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • October 2017
  • by GlobalData

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026SummaryAlzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized ...

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • December 2017
  • by GlobalData

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026SummaryChronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and ...

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • November 2017
  • by GlobalData

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026SummaryProstate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, ...


Download Unlimited Documents from Trusted Public Sources

Type 2 Diabetes Statistics in the UK

  • January 2018
    10 pages
  • Diabetes  

    Type 2 Diabetes  

  • United Kingdom  

View report >

Hospital Markets

  • January 2018
    17 pages
  • Hospital  

    Cardiology  

    Cardiovascular ...  

  • United States  

    United Kingdom  

    Netherlands  

View report >

Global HIV AIDS Statistics

  • January 2018
    87 pages
  • HIV AIDS  

    Infectious Dise...  

    Mortality  

  • World  

    United States  

View report >

Related Market Segments :

Epidemiology

Hospital

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.